JP5745870B2 - Collagen gel contraction promoter - Google Patents

Collagen gel contraction promoter Download PDF

Info

Publication number
JP5745870B2
JP5745870B2 JP2011011630A JP2011011630A JP5745870B2 JP 5745870 B2 JP5745870 B2 JP 5745870B2 JP 2011011630 A JP2011011630 A JP 2011011630A JP 2011011630 A JP2011011630 A JP 2011011630A JP 5745870 B2 JP5745870 B2 JP 5745870B2
Authority
JP
Japan
Prior art keywords
skin
collagen gel
extract
collagen
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011011630A
Other languages
Japanese (ja)
Other versions
JP2012153615A (en
JP2012153615A5 (en
Inventor
真由美 武谷
真由美 武谷
一ノ瀬 進
進 一ノ瀬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP2011011630A priority Critical patent/JP5745870B2/en
Publication of JP2012153615A publication Critical patent/JP2012153615A/en
Publication of JP2012153615A5 publication Critical patent/JP2012153615A5/ja
Application granted granted Critical
Publication of JP5745870B2 publication Critical patent/JP5745870B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • General Preparation And Processing Of Foods (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

本発明は、コラーゲンゲル収縮促進剤、皮膚の老化予防又は改善剤、皮膚の弾力、ハリ又はタルミの改善剤、皮膚の引き締め剤及び皮膚の創傷治癒剤に関する。   The present invention relates to a collagen gel contraction promoter, an agent for preventing or improving skin aging, an agent for improving skin elasticity, elasticity or talmi, a skin tightening agent, and a skin wound healing agent.

皮膚は表皮、真皮、皮下組織の3層に主に分けられ、それらのうち真皮は皮膚の構造の維持に極めて重要であり、コラーゲンやエラスチンといった線維により強固かつ柔軟に造られ、真皮結合組織を形成している。これらコラーゲンやエラスチンといった結合組織の線維を構成するタンパク質は、線維芽細胞により合成/分解されている。線維芽細胞はこれらコラーゲン等の線維と相互作用することにより結合組織の状態をコントロールしている。   The skin is mainly divided into three layers: epidermis, dermis, and subcutaneous tissue. Among them, the dermis is extremely important for maintaining the structure of the skin, and it is made strong and flexible by fibers such as collagen and elastin, and the dermal connective tissue is Forming. Proteins constituting connective tissue fibers such as collagen and elastin are synthesized / degraded by fibroblasts. Fibroblasts control the state of connective tissue by interacting with fibers such as collagen.

通常の線維芽細胞培養条件下、線維芽細胞をコラーゲンゲル中に埋包培養するとコラーゲンゲルは収縮する(例えば、非特許文献1)。コラーゲンゲルの収縮は、細胞数によっても培地中の血清量によっても異なり、またゲル中の線維芽細胞数が多いほど、培地中の血清量が多いほど顕著となる。しかし、このような収縮は、線維芽細胞の存在しないコラーゲンのみのゲルや、リンパ球など浮遊性の細胞を埋包したゲルでは全く起こらない。   When fibroblasts are embedded and cultured in collagen gel under normal fibroblast culture conditions, the collagen gel contracts (for example, Non-Patent Document 1). Collagen gel contraction varies depending on the number of cells and the amount of serum in the medium, and becomes more noticeable as the number of fibroblasts in the gel increases and the amount of serum in the medium increases. However, such contraction does not occur at all in a collagen-only gel without fibroblasts or a gel in which floating cells such as lymphocytes are embedded.

皮膚の老化に関しては、老齢者由来の線維芽細胞では若年者由来の細胞と比較してゲルの収縮が低下することが知られており、老化によりゲルの収縮能が低下することが明らかとなっている(例えば、非特許文献2)。コラーゲンゲルの収縮能が低下することは、真皮結合組織を以前の若い頃のように収縮させて、引き締まった状態で維持することが困難となることを示している。実際、例えば、老化するに従い、頬や首筋、腕、その他各部の皮膚に若い頃にはあまり認められなかったタルミが形成されることは周知の事実である。   Regarding skin aging, it is known that fibroblasts derived from the elderly have reduced gel contraction compared to cells derived from the young, and it has become clear that aging reduces the ability of the gel to contract. (For example, Non-Patent Document 2). A decrease in the contractility of the collagen gel indicates that it is difficult to maintain the dermal connective tissue in a tight state by contracting as in the previous youth. In fact, for example, as it ages, it is a well-known fact that tarmi, which was not recognized when it was young, was formed on the skin of the cheeks, neck, arms and other parts.

このようなことから、皮膚の真皮結合組織が収縮力を失い、さらには強度、弾力性を失い、結果としてタルミに至ると考えられる。従って、線維芽細胞を埋包したコラーゲンゲルの収縮能を高め、さらにはゲルの形成強度を高めることができれば、真皮結合組織をより収縮させ、引き締め、強度を増加させることで、若い頃のような皮膚状態を維持することができると考えられる。また、低下した皮膚の弾力性及びハリ、老化によるタルミが改善され、皮膚を引き締めることができ、さらには真皮結合組織の破壊に起因する創傷の治癒を促進することもできると考えられる。このような事情からコラーゲンゲルの収縮促進剤の開発が望まれていた。   For this reason, it is considered that the dermal connective tissue of the skin loses its contractile force and further loses its strength and elasticity, resulting in tarmi. Therefore, if the contractility of the collagen gel embedded with fibroblasts can be increased, and further the gel formation strength can be increased, the dermal connective tissue can be further contracted, tightened, and increased in strength, as in a young age. It is thought that a healthy skin state can be maintained. Further, it is considered that the reduced elasticity and firmness of the skin and the talmi due to aging can be improved, the skin can be tightened, and further the healing of the wound caused by the destruction of the dermal connective tissue can be promoted. Under such circumstances, development of a collagen gel shrinkage accelerator has been desired.

従来から、線維芽細胞埋包コラーゲンゲルの収縮を促進する物質としては、血清や、エンドセリン(例えば、非特許文献3)、トランスフォーミンググロースファクタβ(例えば、非特許文献4)、プレイトレットグロースファクタ等の成長促進因子、レチノイン酸等の化合物が知られているが、経皮吸収性や安定性、安全性、価格の問題があり、また効果も十分ではなかった。   Conventionally, as a substance that promotes contraction of a fibroblast-embedded collagen gel, serum, endothelin (for example, Non-Patent Document 3), transforming growth factor β (for example, Non-Patent Document 4), platelet growth factor Although compounds such as growth promoting factors such as retinoic acid are known, there are problems of transdermal absorbability, stability, safety and price, and the effect is not sufficient.

一方、タケニグサはケシ科の植物で、消腫、解毒、殺虫、止痒、抗真菌の作用等があることが知られている。また、オヒルムシロはヒルムシロ科の浮葉性多年草である。
しかしながら、これらの植物とコラーゲンゲル収縮促進、さらには皮膚の老化予防又は改善との関係については知られていない。
On the other hand, bamboo rush is a plant of the poppy family and is known to have antitumor, detoxification, insecticidal, antifungal and antifungal actions. Ohirumushiro is a floating leaf perennial plant belonging to the family Amuraceae.
However, the relationship between these plants and collagen gel contraction promotion, as well as prevention or improvement of skin aging is not known.

Review:E.Bell et al.J.Invest.Dermatol.,81,2s(1983)Review: E.M. Bell et al. J. et al. Invest. Dermatol. , 81, 2s (1983) M.Yamato,et al.Mech.Ageing Dev.67,149(1993)M.M. Yamato, et al. Mech. Ageing Dev. 67, 149 (1993) C.Guidry et al.J.Cell Biol.,115,873(1991)C. Guidry et al. J. et al. Cell Biol. 115, 873 (1991) R.Montesano et al.Pro.Natl,Acad.Sci.USA,85,4894(1988)R. Montesano et al. Pro. Natl, Acad. Sci. USA, 85, 4894 (1988)

本発明は、コラーゲンゲル収縮促進剤を提供することに関する。   The present invention relates to providing a collagen gel contraction promoter.

本発明者らは、ヒト皮膚線維芽細胞コラーゲン埋包培養系を用いてコラーゲンゲル収縮促進効果を有する物質について鋭意検討したところ、タケニグサ及びオヒルムシロの抽出物に優れたコラーゲンゲル収縮促進作用があり、これがコラーゲンゲル収縮促進剤、皮膚老化予防又は改善剤、皮膚の弾力、ハリ又はタルミ改善剤、皮膚の引き締め剤、及び皮膚の創傷治癒剤として有用であることを見出した。   The present inventors have intensively studied a substance having a collagen gel contraction accelerating effect using a human skin fibroblast collagen-embedded culture system. It has been found that this is useful as a collagen gel contraction promoter, a skin aging preventive or ameliorating agent, a skin elasticity, a firmness or talmi improving agent, a skin tightening agent, and a skin wound healing agent.

すなわち、本発明は、以下の1)〜5)に係るものである。
1)タケニグサ、オヒルムシロ及びそれらの抽出物からなる群より選択される少なくとも1種を有効成分とするコラーゲンゲル収縮促進剤。
2)タケニグサ、オヒルムシロ及びそれらの抽出物からなる群より選択される少なくとも1種を有効成分とする皮膚の老化予防又は改善剤。
3)タケニグサ、オヒルムシロ及びそれらの抽出物からなる群より選択される少なくとも1種を有効成分とする皮膚の弾力、ハリ又はタルミ改善剤。
4)タケニグサ、オヒルムシロ及びそれらの抽出物からなる群より選択される少なくとも1種を有効成分とする皮膚の引き締め剤。
5)タケニグサ、オヒルムシロ及びそれらの抽出物からなる群より選択される少なくとも1種を有効成分とする皮膚の創傷治癒剤。
That is, the present invention relates to the following 1) to 5).
1) A collagen gel contraction promoter comprising as an active ingredient at least one selected from the group consisting of bamboo rush, leeks and their extracts.
2) A skin aging preventive or ameliorating agent comprising as an active ingredient at least one selected from the group consisting of bamboo rush, cabbage, and extracts thereof.
3) A skin elasticity, elasticity or sagging improving agent comprising at least one selected from the group consisting of Bamboo cristatus, Oyrum shiro and their extracts as an active ingredient.
4) A skin tightening agent comprising as an active ingredient at least one selected from the group consisting of Bamboo cristatus, Oyrus shiro and their extracts.
5) A wound healing agent for skin comprising, as an active ingredient, at least one selected from the group consisting of bamboo rush, cabbage, and extracts thereof.

本発明のコラーゲンゲル収縮促進剤等は、皮膚の老化予防又は改善、低下した皮膚の弾力性及びハリの改善、老化による皮膚のタルミ、皮膚の引き締め及び皮膚の創傷治癒効果を発揮し得る医薬品、医薬部外品、化粧品として、或いはこれらへ配合するための素材又は製剤として有用である。   Collagen gel contraction promoter and the like of the present invention include prevention or improvement of skin aging, improvement of reduced skin elasticity and elasticity, skin talmi due to aging, skin tightening and skin wound healing effect, It is useful as a quasi-drug, cosmetic, or as a material or formulation for blending into these.

タケニグサ抽出物又はオヒルムシロ抽出物によるコラーゲンゲル収縮促進作用。Collagen gel contraction-promoting action by bamboo rush extract or cabbage extract.

本明細書において「コラーゲンゲル」とは、コラーゲンと細胞成分を含有するゲル状の組成物であり、コラーゲンと細胞成分とを含むゲル組成物、細胞のインビトロ培養物、及び生体の真皮における線維芽細胞と周辺の細胞外マトリクスとを含む構造物を包含する。   As used herein, “collagen gel” is a gel-like composition containing collagen and cellular components, gel composition containing collagen and cellular components, in vitro culture of cells, and fibroblasts in the dermis of living organisms. Includes structures comprising cells and the surrounding extracellular matrix.

本明細書において、「非治療的」とは、医療行為、すなわち治療による人体への処理行為を含まない概念である。   In the present specification, “non-therapeutic” is a concept that does not include a medical act, that is, a treatment act on the human body by treatment.

本明細書において、「改善」とは、疾患、症状又は状態の好転、疾患、症状又は状態の悪化の防止又は遅延、あるいは疾患又は症状の進行の逆転、防止又は遅延をいう。   As used herein, “improvement” refers to improvement of a disease, symptom or condition, prevention or delay of worsening of the disease, symptom or condition, or reversal, prevention or delay of progression of a disease or symptom.

本明細書において、「予防」とは、個体における疾患若しくは症状の発症の防止又は遅延、あるいは個体の疾患若しくは症状の発症の危険性を低下させることをいう。   As used herein, “prevention” refers to preventing or delaying the onset of a disease or symptom in an individual, or reducing the risk of developing an individual's disease or symptom.

本明細書において、タケニグサとは、ケシ科の博落回(タケニグサ、Macleya cordata(Willd.)R.Br)を、オヒルムシロとはヒルムシロ科の眼子菜(オヒルムシロ、Potamogeton natans L)をそれぞれ意味する。また、タケニグサ抽出物又はオヒルムシロ抽出物とは、タケニグサ又はオヒルムシロから得られた抽出物を意味する。
斯かる植物は、それらのいずれの任意の部位、例えば全草、葉、茎、芽、花、蕾、木質部、樹皮、地衣体、根、根茎、仮球茎、球茎、塊茎、種子、果実、菌核若しくは樹脂等、又はそれらの組み合わせを使用することができるが、タケニグサ、オヒルムシロの両植物共に、全草を用いるのが好ましい。
上記部位は、そのまま抽出工程に付されてもよく、又は粉砕、切断若しくは乾燥された後に抽出工程に付されてもよい。該抽出物は天然成分由来であり安全性も高い。
In the present specification, the bamboo rush means a poppy family (Macleya corda (Wild.) R. Br), and the scallop is a scallop ophthalmia (Potamogeton natans L). . Moreover, a bamboo rush extract or a scallop extract means an extract obtained from a bamboo squirrel or a scallop.
Such plants can be any part of them, such as whole grass, leaves, stems, buds, flowers, buds, wood parts, bark, lichens, roots, rhizomes, corms, corms, tubers, seeds, fruits, fungi A nucleus, a resin, or the like, or a combination thereof can be used, but it is preferable to use the whole plant for both the bamboo rush and the scallop.
The part may be subjected to the extraction step as it is, or may be subjected to the extraction step after being pulverized, cut or dried. The extract is derived from natural ingredients and has high safety.

タケニグサ又はオヒルムシロ抽出物を得る抽出手段は、具体的には、固液抽出、液液抽出、浸漬、煎出、浸出、還流抽出、超音波抽出、マイクロ波抽出、攪拌等の手段を用いることができる。例えば、浸漬の好適な一例として、10〜50℃で、1時間〜14日間の浸漬が挙げられる。また、抽出時間を短縮する場合には、攪拌を伴う固液抽出が望ましい。この固液抽出の好適な条件の一例としては、10〜100℃(好ましくは70〜90℃)下、100〜400r/minで1〜30分間の攪拌が挙げられる。
抽出物の酸化を防止するため、煮沸脱気や窒素ガス等の不活性ガスを通気して溶存酸素を除去しつつ、いわゆる非酸化的雰囲気下で抽出する手段を併用してもよい。
Specific examples of the extraction means for obtaining the bamboo shoot or leeches extract include solid-liquid extraction, liquid-liquid extraction, immersion, decoction, leaching, reflux extraction, ultrasonic extraction, microwave extraction, stirring, and the like. it can. For example, as a suitable example of immersion, immersion at 10 to 50 ° C. for 1 hour to 14 days can be mentioned. Moreover, when shortening extraction time, solid-liquid extraction with stirring is desirable. Examples of suitable conditions for this solid-liquid extraction include stirring at 10 to 100 ° C. (preferably 70 to 90 ° C.) at 100 to 400 r / min for 1 to 30 minutes.
In order to prevent the oxidation of the extract, a means for extracting under a so-called non-oxidizing atmosphere while removing dissolved oxygen by bubbling degassing or inert gas such as nitrogen gas may be used in combination.

抽出のための溶剤には、極性溶剤、非極性溶剤のいずれをも使用することができる。溶剤の具体例としては、例えば、水;メタノール、エタノール、プロパノール、ブタノール等のアルコール類;プロピレングリコール、ブチレングリコール等の多価アルコール類;アセトン、メチルエチルケトン等のケトン類;酢酸メチル、酢酸エチル等のエステル類;テトラヒドロフラン、ジエチルエーテル等の鎖状及び環状エーテル類;ポリエチレングリコール等のポリエーテル類;スクワラン、ヘキサン、シクロヘキサン、石油エーテル等の炭化水素類;トルエン等の芳香族炭化水素類;ジクロロメタン、クロロホルム、ジクロロエタン等のハロゲン化炭化水素類;及び超臨界二酸化炭素;ピリジン類;油脂、ワックス等その他オイル類等の有機溶剤;ならびにこれらの混合物が挙げられる。好適には、水、アルコール類及びその水溶液が挙げられ、アルコール類としてはエタノールが好ましい。より好ましい溶剤は、水及びエタノール水溶液である。   As the solvent for extraction, either a polar solvent or a nonpolar solvent can be used. Specific examples of the solvent include water; alcohols such as methanol, ethanol, propanol and butanol; polyhydric alcohols such as propylene glycol and butylene glycol; ketones such as acetone and methyl ethyl ketone; methyl acetate and ethyl acetate Esters; linear and cyclic ethers such as tetrahydrofuran and diethyl ether; polyethers such as polyethylene glycol; hydrocarbons such as squalane, hexane, cyclohexane and petroleum ether; aromatic hydrocarbons such as toluene; dichloromethane and chloroform And halogenated hydrocarbons such as dichloroethane; and supercritical carbon dioxide; pyridines; organic solvents such as oils and fats, other oils such as wax; and mixtures thereof. Preferable examples include water, alcohols and aqueous solutions thereof, and ethanol is preferable as the alcohols. More preferred solvents are water and an aqueous ethanol solution.

抽出のための溶剤としてエタノール水溶液を使用する場合には、エタノール水溶液と水との配合割合(容量比)としては、0.001〜100:99.999〜0が好ましく、5〜95:95〜5がより好ましく、20〜80:80〜20がさらに好ましく、30〜70:70〜30がさらにより好ましく、40〜60:60〜40がなお好ましい。エタノール水溶液の場合、エタノール濃度が40〜60容量%であることが好ましい。
溶剤の使用量としては、タケニグサ又はオヒルムシロ(乾燥質量換算)1gに対して1〜100mLが好ましく、抽出時間としては、1分間〜100日間が好ましく、30分間〜10日間がより好ましい。このときの抽出温度は、0℃〜溶媒沸点、より好ましくは20〜100℃、さらに好ましくは50〜100℃、さらにより好ましくは70〜90℃である。
When an aqueous ethanol solution is used as a solvent for extraction, the mixing ratio (volume ratio) of the aqueous ethanol solution and water is preferably 0.001 to 100: 99.999-0, and 5 to 95:95 to 5 is more preferable, 20 to 80:80 to 20 is more preferable, 30 to 70:70 to 30 is still more preferable, and 40 to 60:60 to 40 is still more preferable. In the case of an ethanol aqueous solution, the ethanol concentration is preferably 40 to 60% by volume.
As a usage-amount of a solvent, 1-100 mL is preferable with respect to 1 g of a bamboo rush or a cabbage (dry mass conversion), As extraction time, 1 minute-100 days are preferable, and 30 minutes-10 days are more preferable. The extraction temperature at this time is 0 ° C. to the boiling point of the solvent, more preferably 20 to 100 ° C., still more preferably 50 to 100 ° C., and still more preferably 70 to 90 ° C.

斯くして得られる植物抽出物は、抽出液や画分をそのまま用いてもよく、適宜な溶媒で希釈した希釈液として用いてもよく、或いは濃縮エキスや乾燥粉末としたり、ペースト状に調製したものでもよい。また、凍結乾燥し、用時に、通常抽出に用いられる溶剤、例えば水、エタノール、プロピレングリコール、ブチレングリコール、水・エタノール混液、水・プロピレングリコール混液、水・ブチレングリコール混液等の溶剤で希釈して用いることもできる。また、リポソーム等のベシクルやマイクロカプセル等に内包させて用いることもできる。   The plant extract thus obtained may be used as it is as the extract or fraction, may be used as a diluted solution diluted with an appropriate solvent, or may be a concentrated extract or dry powder, or prepared in a paste form. It may be a thing. Also, freeze-dry and dilute with a solvent usually used for extraction, such as water, ethanol, propylene glycol, butylene glycol, water / ethanol mixture, water / propylene glycol mixture, water / butylene glycol mixture, etc. It can also be used. It can also be used by encapsulating in vesicles such as liposomes or microcapsules.

また、タケニグサ又はオヒルムシロ抽出物は、食品上・医薬品上許容し得る規格に適合し本発明の効果を発揮するものであれば粗精製物であってもよく、さらに得られた粗精製物を公知の分離精製方法を適宜組み合わせてこれらの純度を高めてもよい。精製手段としては、有機溶剤沈殿、遠心分離、限界濾過膜、高速液体クロマトグラフやカラムクロマトグラフ等が挙げられる。   In addition, the bamboo rush or euglena extract may be a crude purified product as long as it conforms to food and pharmaceutical acceptable standards and exhibits the effects of the present invention, and the obtained crude purified product is publicly known. These separation and purification methods may be combined as appropriate to increase their purity. Examples of the purification means include organic solvent precipitation, centrifugation, ultrafiltration membrane, high performance liquid chromatograph, column chromatograph and the like.

後記実施例で示すとおり、本発明の植物又はその抽出物は、線維芽細胞を埋包したコラーゲンゲルの収縮促進作用を有する。従って、本発明の植物又はその抽出物は、コラーゲンゲル収縮促進のために使用することができる。
また、前述したとおり、通常の線維芽細胞培養条件下、線維芽細胞をコラーゲンゲル中に埋包培養するとコラーゲンゲルは収縮する(例えば、非特許文献1)。そして、皮膚の老化に関しては、老齢者由来の線維芽細胞では若年者由来の細胞と比較してゲルの収縮が低下することが知られており、老化によりゲルの収縮能が低下することが明らかとなっている(例えば、非特許文献2)。線維芽細胞を埋包したコラーゲンゲルの収縮能を高め、さらにはゲルの形成強度を高めることができれば、低下した皮膚の弾力性及びハリが改善され、老化による皮膚のタルミを改善でき、また、皮膚を引き締めることができると考えられている。また、真皮結合組織の破壊に起因する創傷の治癒を促進することもできる。
従って、本発明の植物又はその抽出物は、低下した皮膚の弾力性及びハリの改善、老化による皮膚のタルミの改善、皮膚の引き締め、ひいては皮膚の老化を予防又は改善をするため、或いは真皮結合組織の破壊に起因する創傷の治癒のために使用することができる。当該使用は、ヒト若しくは非ヒト動物、又はそれらに由来する検体における使用であり得、また治療的使用であっても非治療的使用であってもよい。
As will be described in Examples below, the plant of the present invention or an extract thereof has a contraction promoting action of a collagen gel in which fibroblasts are embedded. Therefore, the plant of this invention or its extract can be used for collagen gel contraction promotion.
Further, as described above, when fibroblasts are embedded and cultured in collagen gel under normal fibroblast culture conditions, the collagen gel contracts (for example, Non-Patent Document 1). Regarding skin aging, it is known that fibroblasts derived from elderly people have reduced gel contraction compared to cells derived from young people, and it is clear that aging reduces the ability of the gel to contract. (For example, Non-Patent Document 2). If the contractility of the collagen gel embedded with fibroblasts can be increased, and further the gel formation strength can be increased, the reduced elasticity and firmness of the skin can be improved, the skin talmi due to aging can be improved, It is believed that it can tighten the skin. It can also promote the healing of wounds resulting from the destruction of the dermal connective tissue.
Therefore, the plant of the present invention or an extract thereof can be used to improve reduced skin elasticity and firmness, to improve skin talmi due to aging, to tighten skin, and thus to prevent or improve skin aging, or to bind dermis It can be used for wound healing due to tissue destruction. The use can be in humans or non-human animals, or specimens derived therefrom, and can be therapeutic or non-therapeutic.

また、本発明の植物又はその抽出物は、コラーゲンゲル収縮促進剤、皮膚の老化予防又は改善剤、皮膚の弾力、ハリ又はタルミ改善剤、皮膚の引き締め剤、皮膚の創傷治癒剤等(以下、「コラーゲンゲル収縮促進剤等」)として使用することができ、さらにこれらの剤を製造するために使用することができる。このとき、当該コラーゲンゲル収縮促進剤等には、当該タケニグサ、オヒルムシロ及びそれらの抽出物からなる群より選択される少なくとも1種を単独で、又はこれ以外に、必要に応じて適宜選択した担体等の、配合すべき後述の対象物において許容されるものを使用してもよい。なお、当該製剤は配合すべき対象物に応じて常法により製造することができる。   Further, the plant of the present invention or an extract thereof includes a collagen gel contraction promoter, a skin aging preventive or ameliorating agent, a skin elasticity, a firmness or a talmi improving agent, a skin tightening agent, a skin wound healing agent, etc. Can be used as “collagen gel shrinkage promoters” and the like, and can also be used to produce these agents. At this time, the collagen gel contraction promoter or the like is at least one selected from the group consisting of the bamboo rush, leeches and extracts thereof alone, or in addition to this, a carrier appropriately selected as necessary Those which are acceptable in the below-mentioned objects to be blended may be used. In addition, the said formulation can be manufactured by a conventional method according to the target object which should be mix | blended.

当該コラーゲンゲル収縮促進剤等は、皮膚の弾力、ハリ又はタルミの改善、皮膚の引き締め、ひいては皮膚老化の予防又は改善、或いは真皮結合組織の破壊に起因する創傷の治癒等の各効果を発揮する、ヒト若しくは動物用の医薬品、医薬部外品、化粧品、食品等の有効成分として配合して使用することができる。   The collagen gel contraction promoter, etc. exerts various effects such as improvement of skin elasticity, elasticity or tarmi, tightening of the skin, and prevention or improvement of skin aging, or healing of wounds caused by destruction of dermal connective tissue. It can be used as an active ingredient in human or veterinary drugs, quasi drugs, cosmetics, foods and the like.

本発明のコラーゲンゲル収縮促進剤等を医薬品の有効成分として用いる場合、当該医薬品は任意の投与形態で投与され得る。投与形態としては、例えば注射剤、坐剤、吸入薬、経皮吸収剤、外用剤等による非経口投与又は錠剤、カプセル剤、顆粒剤、散剤、シロップ剤等による経口投与が挙げられる。
このような種々の剤型の医薬製剤を調製するには、本発明のコラーゲンゲル収縮促進剤等を単独で、又は他の薬学的に許容される賦形剤、結合剤、増量剤、崩壊剤、界面活性剤、滑沢剤、分散剤、緩衝剤、保存剤、嬌味剤、香料、被膜剤、担体、希釈剤等を適宜組み合わせて用いることができる。
When the collagen gel contraction promoter of the present invention is used as an active ingredient of a pharmaceutical product, the pharmaceutical product can be administered in any dosage form. Examples of the dosage form include parenteral administration such as injections, suppositories, inhalants, transdermal absorption agents, external preparations, or oral administration such as tablets, capsules, granules, powders, syrups and the like.
In order to prepare such pharmaceutical preparations of various dosage forms, the collagen gel contraction promoter of the present invention alone or other pharmaceutically acceptable excipient, binder, extender, disintegrant , Surfactants, lubricants, dispersants, buffers, preservatives, flavoring agents, fragrances, coating agents, carriers, diluents, and the like can be used in appropriate combinations.

これらの投与形態のうち、好ましい形態は非経口投与であり、コラーゲンゲル収縮促進剤等を含む非経口投与用製剤中のタケニグサ、オヒルムシロ又はそれらの抽出物の含有量(抽出物の乾燥物換算)は、一般的に0.00001〜10質量%とするのが好ましく、0.0001〜1質量%とするのがより好ましい。   Among these dosage forms, the preferred form is parenteral administration, and the content of bamboo rush, scallop or extract thereof in a preparation for parenteral administration containing a collagen gel contraction promoter, etc. (in terms of dry matter of the extract) Is generally preferably 0.00001 to 10% by mass, and more preferably 0.0001 to 1% by mass.

本発明のコラーゲンゲル収縮促進剤等を医薬部外品や化粧料の有効成分として用いる場合は、その形態は、皮膚外用剤、洗浄剤、メイクアップ化粧料等とすることができ、使用方法に応じて、ローション、乳液、ゲル、クリーム、軟膏剤、粉末、顆粒等の種々の剤型で提供することができる。このような種々の剤型の医薬部外品や化粧料は、本発明のタケニグサ、オヒルムシロ及びそれらの抽出物から選ばれる1種以上と、医薬部外品、皮膚化粧料及び洗浄料に配合される、油性成分、保湿剤、粉体、色素、乳化剤、可溶化剤、洗浄剤、紫外線吸収剤、増粘剤、薬剤(例えば、抗炎症剤、殺菌剤、酸化防止剤、ビタミン類、脂肪代謝促進作用又は脱共役蛋白質発現促進作用が知られている薬物或いは天然物)、香料、樹脂、防菌防黴剤、植物抽出物、アルコール類等を適宜組み合わせることにより調製することができる。   When the collagen gel shrinkage accelerator of the present invention is used as an active ingredient of a quasi-drug or cosmetic, the form can be a skin external preparation, a cleaning agent, a makeup cosmetic, etc. Accordingly, it can be provided in various dosage forms such as lotion, emulsion, gel, cream, ointment, powder, granule and the like. Such quasi-drugs and cosmetics in various dosage forms are blended in one or more selected from the bamboo rush, Ohirumushiro and their extracts of the present invention, quasi-drugs, skin cosmetics and cleansing agents. Oil components, moisturizers, powders, pigments, emulsifiers, solubilizers, detergents, UV absorbers, thickeners, drugs (eg anti-inflammatory agents, bactericides, antioxidants, vitamins, fat metabolism It can be prepared by appropriately combining a promoting agent or a drug or natural product known to have an uncoupling protein expression promoting effect), a fragrance, a resin, an antifungal agent, a plant extract, an alcohol and the like.

当該医薬部外品、化粧料中のタケニグサ、オヒルムシロ又はそれらの抽出物(抽出物の乾燥物換算)の含有量は、一般的に0.00001〜10質量%とするのが好ましく、0.0001〜1質量%とするのがより好ましい。   In general, the content of the quasi-drug, the bamboo rush, the silkworm or the extract thereof (in terms of a dried product of the extract) is preferably 0.00001 to 10% by mass, 0.0001 It is more preferable to set it to 1 mass%.

本発明のコラーゲンゲル収縮促進剤等を食品の有効成分として用いる場合、当該食品の形態は、パン類、ケーキ類、麺類、菓子類、ゼリー類、冷凍食品、アイスクリーム類、乳製品、飲料などの各種食品の他、上述した経口投与製剤と同様の形態(錠剤、カプセル剤、シロップ等)が挙げられる。
種々の形態の食品を調製するには、本発明のコラーゲンゲル収縮促進剤等を単独で、又は他の食品材料や、溶剤、軟化剤、油、乳化剤、防腐剤、香科、安定剤、着色剤、酸化防止剤、保湿剤、増粘剤等を適宜組み合わせて用いることができる。当該食品中のタケニグサ、オヒルムシロ又はそれらの抽出物の含有量(抽出物の乾燥物換算)は、一般的に0.01〜100質量%とするのが好ましく、0.1〜100質量%とするのがより好ましく、更に好ましくは1〜100質量%とするのが好ましい。
When using the collagen gel shrinkage accelerator of the present invention as an active ingredient of food, the form of the food is bread, cakes, noodles, confectionery, jelly, frozen food, ice cream, dairy product, beverage, etc. In addition to these various foods, the same forms (tablets, capsules, syrups, etc.) as the above-mentioned oral preparations can be mentioned.
To prepare various forms of food, the collagen gel shrinkage promoter of the present invention alone or other food materials, solvents, softeners, oils, emulsifiers, preservatives, fragrances, stabilizers, colorings An agent, an antioxidant, a humectant, a thickener and the like can be used in appropriate combination. In general, the content of the bamboo shoots, cabbage or extract thereof (in terms of dry matter of the extract) in the food is preferably 0.01 to 100% by mass, and preferably 0.1 to 100% by mass. Is more preferable, and more preferably 1 to 100% by mass.

製造例1
(1)タケニグサ抽出物の調製
タケニグサ150gに、50(v/v)%エタノール2250mLを加えて、85℃で3時間抽出後、濾過して粗抽出液を得た後、濃縮乾固して抽出固形分22.0gを得た。
この抽出固形分を蒸発残分1.0(w/v)%となるよう50(v/v)%エタノールに溶解し、タケニグサ50(v/v)%エタノール抽出物を調製した。
Production Example 1
(1) Preparation of bamboo rush extract Add 2250 mL of 50 (v / v)% ethanol to 150 gram of bamboo rush, extract at 85 ° C for 3 hours, filter to obtain a crude extract, concentrate to dryness and extract 22.0 g of solid content was obtained.
This extracted solid was dissolved in 50 (v / v)% ethanol so that the evaporation residue was 1.0 (w / v)% to prepare a bamboo extract 50 (v / v)% ethanol extract.

(2)オヒルムシロ抽出物の調製
オヒルムシロ200gに、50(v/v)%エタノール2200mLを加えて、85℃で3時間抽出後、濾過して粗抽出液を得た後、濃縮乾固して抽出固形分12.0gを得た。
この抽出固形分を蒸発残分1.0(w/v)%となるよう50(v/v)%エタノールに溶解し、オヒルムシロ50(v/v)%エタノール抽出物を調製した。
(2) Preparation of Oyorumushiro Extract 2200 mL of 50 (v / v)% ethanol was added to 200 g of Oyorumushiro, extracted for 3 hours at 85 ° C., filtered to obtain a crude extract, concentrated to dryness and extracted. 12.0 g of solid content was obtained.
This extracted solid was dissolved in 50 (v / v)% ethanol so as to have an evaporation residue of 1.0 (w / v)% to prepare an extract of Ohirumushiro 50 (v / v)%.

試験例1 コラーゲンゲル収縮促進能の測定
コラーゲンゲルは文献「J.Cell Science,102,315(1992)」または「J.Invest.Dermatol,93,792(1989)」を参考にした方法で作製した。すなわち、氷冷下コラーゲンゲル溶液(新田ゼラチン社製、tape I−A(3.0mg/mL,pH=3))にHEPES(0.01Mの水酸化ナトリウムを含む)、DMEM(GIBCO DMEM,low glucose)5倍濃縮溶液、FBS(5%、Fatal Bovine Serum)、精製水を加え、十分に攪拌中和した後、最終濃度0.001、0.0005、0.0001質量%(乾燥固形換算質量%)となるように、被験物質(製造例1で得た各植物抽出物)或いはコントロールとして0.05(v/v)%エタノールを加え、最後にヒト皮膚線維芽細胞(ヒト包皮由来、クラボウ社)の懸濁液を1×105cells/wellとなるように加えた。十分に攪拌し、気泡を取り除いた後、24穴プレートに各穴0.6mLずつ注入し、直ちに37℃でゲル化させた。この際のコラーゲン濃度は1.5mg/mLに調製した。
24時間後にプレートの各穴に液体培地を加え、ゲルの周囲を剥離して、その後さらに37℃で48時間培養した。
Test Example 1 Measurement of Collagen Gel Contraction Promoting Ability Collagen gel was prepared by a method referring to literature “J. Cell Science, 102, 315 (1992)” or “J. Invest. Dermatol, 93, 792 (1989)”. . That is, HEPES (containing 0.01 M sodium hydroxide), DMEM (GIBCO DMEM, manufactured by Nitta Gelatin Co., Ltd., tape IA (3.0 mg / mL, pH = 3)) under ice-cooling. low glucose) 5-fold concentrated solution, FBS (5%, Fatal Bovine Serum) and purified water, and after sufficiently neutralizing with stirring, final concentrations of 0.001, 0.0005, 0.0001 mass% (in terms of dry solids) Mass%)), 0.05 (v / v)% ethanol was added as a test substance (each plant extract obtained in Production Example 1) or as a control, and finally human skin fibroblasts (derived from human foreskin, Kurabo Industries Co., Ltd.) suspension was added to 1 × 10 5 cells / well. After sufficiently stirring and removing bubbles, 0.6 mL of each hole was poured into a 24-well plate and immediately gelled at 37 ° C. The collagen concentration at this time was adjusted to 1.5 mg / mL.
After 24 hours, liquid medium was added to each hole of the plate, the periphery of the gel was peeled off, and then further cultured at 37 ° C. for 48 hours.

48時間培養後、天秤にてゲルの重量を計測した。
各植物抽出物のコラーゲンゲル収縮促進効果は、各植物抽出物を添加したゲルの重量をコントロールの重量で補正した値を収縮促進率(%)として評価した。
After culturing for 48 hours, the weight of the gel was measured with a balance.
The collagen gel contraction promoting effect of each plant extract was evaluated as a contraction promotion rate (%) by correcting the weight of the gel added with each plant extract with the weight of the control.

図1に示すとおり、タケニグサ及びオヒルムシロにより、コラーゲンゲルの重量、すなわち体積が小さくなり、これら2種類のエキスによるコラーゲンゲル収縮促進効果が認められた。   As shown in FIG. 1, the weight of the collagen gel, that is, the volume, was reduced by the bamboo rush and the silkworm, and the collagen gel contraction promoting effect by these two types of extracts was recognized.

Claims (1)

オヒルムシロ及その抽出物からなる群より選択される少なくとも1種を有効成分とするコラーゲンゲル収縮促進剤。 Ohirumushi b及 beauty collagen gel contraction accelerator comprising as an active ingredient, at least one selected from the group consisting of the extract.
JP2011011630A 2011-01-24 2011-01-24 Collagen gel contraction promoter Active JP5745870B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011011630A JP5745870B2 (en) 2011-01-24 2011-01-24 Collagen gel contraction promoter

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011011630A JP5745870B2 (en) 2011-01-24 2011-01-24 Collagen gel contraction promoter

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014232595A Division JP2015034181A (en) 2014-11-17 2014-11-17 Collagen gel contraction promoting agent

Publications (3)

Publication Number Publication Date
JP2012153615A JP2012153615A (en) 2012-08-16
JP2012153615A5 JP2012153615A5 (en) 2014-02-06
JP5745870B2 true JP5745870B2 (en) 2015-07-08

Family

ID=46835756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011011630A Active JP5745870B2 (en) 2011-01-24 2011-01-24 Collagen gel contraction promoter

Country Status (1)

Country Link
JP (1) JP5745870B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6417113B2 (en) * 2014-05-21 2018-10-31 花王株式会社 Involucrin expression inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01203324A (en) * 1988-02-08 1989-08-16 Vipont Pharmaceut Inc Method for prohibiting bone absorption and collagenase discharge
JPH1072336A (en) * 1996-06-28 1998-03-17 Kao Corp Collagen gel contraction accelerator
SE0200667D0 (en) * 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
JP2005089304A (en) * 2003-09-12 2005-04-07 Nippon Menaade Keshohin Kk Production inhibitor of inflammatory cytokine
JP2010215532A (en) * 2009-03-13 2010-09-30 Ands Corporation Collagen gel contraction promoter
KR102260986B1 (en) * 2009-08-26 2021-06-03 마리 케이 인코포레이티드 Topical skin care formulations comprising plant extracts

Also Published As

Publication number Publication date
JP2012153615A (en) 2012-08-16

Similar Documents

Publication Publication Date Title
FR2938439A1 (en) EXTRACT OF AERIAL PARTS OF OATS HARVESTED BEFORE EPIAISON
KR101787531B1 (en) Composition for preventing hair loss comprising extracts of crude drug complex
JP2003160505A (en) Food and drink as well as external preparation with body fat reducing effect
JP2016160198A (en) Kaempferia parviflora-containing compositions
KR101757469B1 (en) Compositions for promoting hair growth and inhibiting inflammation comprising mixed extracts of natural products
JP6302446B2 (en) Composition for promoting PPARγ expression containing black ginger
JP6055667B2 (en) Collagen production promoter
KR102612017B1 (en) Composition for skin improvement comprising multiple extract
JP5745870B2 (en) Collagen gel contraction promoter
KR20180064202A (en) Composition for preventing, improving or treating atopic dermatitis comprising mixture of Torilis japonica extract and copper tripeptide-1 as effective component
JP2019147824A (en) Kaempferia parviflora-containing compositions
CN112584820A (en) Cosmetic composition for skin moisture containing thyme complex extract as active ingredient
KR102611916B1 (en) Composition for skin improvement comprising multiple extract
KR102458480B1 (en) A composition for stimulating growth of hairs contaning rhynchosia nulubilis complex extracts
JP2016188180A (en) Composition containing specific component
KR102272637B1 (en) Anti-inflammatory composition comprising Prunus pendula for. ascendens (Makino) Ohwi
US20220378688A1 (en) Moisturizing or anti-atopic composition containing fatty acids or fatty acid derivatives
JP2015034181A (en) Collagen gel contraction promoting agent
JP2011032177A (en) Inhibitor of kit cleavage
KR20110089626A (en) Cosmetic composition containing plant extract for improving skin condition
KR20160061601A (en) Cosmetic composition and pharmaceutical composition containing the extract of Corchorus olitorius L, ginko and chlorella
JP2004043393A (en) Vascular endothelial cell growth factor production promoter
KR102443334B1 (en) Composition with Anti-Inflammation, Skin Moisturizing, Pruritis Improving, and Skin Regeneration Property Comprising Complex Extract of Hibiscus Syriacus as Active Ingredient
KR102429214B1 (en) A composition for stimulating growth of hairs contaning natural complex extracts
KR102182710B1 (en) Compositions for Skin Moisture Comprising Extract of Plectranthus tomentosa or Complex Extract thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131212

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150507

R151 Written notification of patent or utility model registration

Ref document number: 5745870

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R151

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250